CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large-scale international multicenter study.
Details
Serval ID
serval:BIB_6C1EDDC275C6
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large-scale international multicenter study.
Journal
Alzheimer's and Dementia
ISSN
1552-5279 (Electronic)
ISSN-L
1552-5260
Publication state
Published
Issued date
2015
Peer-reviewed
Oui
Volume
11
Number
11
Pages
1306-1315
Language
english
Abstract
INTRODUCTION: The aim of this study was to test the diagnostic value of cerebrospinal fluid (CSF) beta-amyloid (Aβ1-42), phosphorylated tau, and total tau (tau) to discriminate Alzheimer's disease (AD) dementia from other forms of dementia.
METHODS: A total of 675 CSF samples collected at eight memory clinics were obtained from healthy controls, AD dementia, subjective memory impairment, mild cognitive impairment, vascular dementia, Lewy body dementia (LBD), fronto-temporal dementia (FTD), depression, or other neurological diseases.
RESULTS: CSF Aβ1-42 showed the best diagnostic accuracy among the CSF biomarkers. At a sensitivity of 85%, the specificity to differentiate AD dementia against other diagnoses ranged from 42% (for LBD, 95% confidence interval or CI = 32-62) to 77% (for FTD, 95% CI = 62-90).
DISCUSSION: CSF Aβ1-42 discriminates AD dementia from FTD, but shows significant overlap with other non-AD forms of dementia, possibly reflecting the underlying mixed pathologies.
METHODS: A total of 675 CSF samples collected at eight memory clinics were obtained from healthy controls, AD dementia, subjective memory impairment, mild cognitive impairment, vascular dementia, Lewy body dementia (LBD), fronto-temporal dementia (FTD), depression, or other neurological diseases.
RESULTS: CSF Aβ1-42 showed the best diagnostic accuracy among the CSF biomarkers. At a sensitivity of 85%, the specificity to differentiate AD dementia against other diagnoses ranged from 42% (for LBD, 95% confidence interval or CI = 32-62) to 77% (for FTD, 95% CI = 62-90).
DISCUSSION: CSF Aβ1-42 discriminates AD dementia from FTD, but shows significant overlap with other non-AD forms of dementia, possibly reflecting the underlying mixed pathologies.
Keywords
Aged, Aged, 80 and over, Alzheimer Disease/cerebrospinal fluid, Alzheimer Disease/diagnosis, Amyloid beta-Peptides/cerebrospinal fluid, Biomarkers/cerebrospinal fluid, Diagnosis, Differential, Female, Humans, Internationality, Male, Middle Aged, Peptide Fragments/cerebrospinal fluid, Phosphorylation, Sensitivity and Specificity, Spinal Puncture, tau Proteins/cerebrospinal fluid
Pubmed
Web of science
Create date
08/02/2016 10:13
Last modification date
20/08/2019 14:26
Usage data
